NEW YORK, Feb. 7, 2017 /PRNewswire/ -- Noble Capital Markets announced today that it has initiated research coverage
Anavex Life Sciences is a biopharmaceutical company developing innovative therapies for neurological disorders and cancer. The company uses its SIGMACEPTOR ™ Discovery Platform to develop novel drugs that target neurological and neurodegenerative diseases, such as Alzheimer's, Parkinsons's, Rett Syndrome and different forms of cancers.
The lead product candidate, ANAVEX 2-73, is on path for a Phase 2/3 in Alzheimer's disease and a Phase 2 study in Rett's Syndrome. In previous trials, ANAVEX 2-73 has exhibited a high affinity and selection to sigma-1 receptors, and has shown synergistic action with other receptors, such as Muscarinic and N-methyl-D-aspartate (NMDA) in clinical trials. The drug has also displayed a favorable side effect profile, which can be beneficial to patients and advantageous when compared to current treatments.
The full report and disclosures can be accessed by clicking here
For further information please contact Steve Rashkin at 561-994-5738 or email@example.com
About Noble Capital Markets (www.noblecapitalmarkets.com)
Noble Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton (HQ), New York and Boston. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences such as the Media, Finance & Investor Conference offered in partnership with the National Association of Broadcasters (NAB).
Members: FINRA, SIPC, MSRB
This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.
Please see disclosure, valuation methods, price charts, and ratings histories available in the complete research report, available by clicking here or contacting Noble Capital Markets at 561-994-5738. The securities covered by or mentioned in the reports involve substantial risk and should generally be purchased only by investors able to accept such risk.
Related Links: www.noblecapitalmarkets.com
Noble Capital Markets is a member of the Financial Industry Regulatory Authority, CRD number 15768.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/noble-capital-markets-initiates-research-coverage-on-anavex-life-sciences-corp-avxl-300403268.html
SOURCE Noble Capital Markets
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All